AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15459518 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy program (Kegel exercises and interferential current) for 5 weeks, 15 sessions
Number of subjects: 48
Study 12440556 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 12440556 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release metoprolol succinate
Number of subjects: 0
Study 12440556 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers (general)
Number of subjects: 0
Study 9606617 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg once daily
Number of subjects: 0
Study 9606617 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day
Number of subjects: 0
Study 9606617 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg/day
Number of subjects: 0
Study 9606617 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 0
Study 9606617 — intervention group
Group type: COMPARATOR
Intervention: Flutamide 250 mg 3 times daily
Number of subjects: 0
Study 9606617 — intervention group
Group type: COMPARATOR
Intervention: Castration
Number of subjects: 0
Study 8562104 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (rewarmed by a new device that acts by both conduction and convection)
Number of subjects: 30
Study 8562104 — intervention group
Group type: COMPARATOR
Intervention: Group B (covered with cotton blankets)
Number of subjects: 30
Study 2368889 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg.kg‐1
Number of subjects: 40
Study 2368889 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 4 mg.kg‐1
Number of subjects: 40
Study 2368889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 324257 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil (average dose 19.7 mg)
Number of subjects: 18
Study 324257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30407567 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscimol infusion
Number of subjects: 3
Study 30407567 — intervention group
Group type: COMPARATOR
Intervention: Vehicle infusion
Number of subjects: 3
Study 30407567 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard epilepsy surgery
Number of subjects: 3
Study 28760058 — intervention group
Group type: EXPERIMENTAL
Intervention: Video information in addition to the regular information leaflet
Number of subjects: 136
Study 28760058 — intervention group
Group type: COMPARATOR
Intervention: Regular information leaflet (Control)
Number of subjects: 136
Study 28760058 — intervention group
Group type: EXPERIMENTAL
Intervention: Video information
Number of subjects: 136
Study 25283350 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS plus mCIMT (n = 10)
Number of subjects: 19
Study 25283350 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS plus mCIMT (n = 9)
Number of subjects: 19
Study 24171300 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream, applied twice a day for 4 weeks
Number of subjects: 60
Study 24171300 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus 0.03% cream, applied twice a day for 4 weeks
Number of subjects: 60
Study 21737767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 150 mg sustained-release once daily
Number of subjects: 60
Study 21737767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19031231 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestion to become a same-sex sibling; administered 2 challenges to the temporary delusion.
Number of subjects: 0
Study 19031231 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestion to become someone similar or dissimilar to themselves (Experiment 1).
Number of subjects: 0
Study 16671518 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive perioperative management (Group B, 226 patients)
Number of subjects: 258
Study 16671518 — intervention group
Group type: COMPARATOR
Intervention: No comprehensive perioperative management (Group A, 32 patients)
Number of subjects: 258
Study 15591456 — intervention group
Group type: EXPERIMENTAL
Intervention: Sialyl Lewis(a) expression levels
Number of subjects: 233
Study 15591456 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 233
Study 11689036 — intervention group
Group type: EXPERIMENTAL
Intervention: Target game (repeated participation)
Number of subjects: 2
Study 11689036 — intervention group
Group type: COMPARATOR
Intervention: Target game (single participation)
Number of subjects: 2
Study 11689036 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group (7-year-olds)
Number of subjects: 2
Study 11689036 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group (4-year-olds)
Number of subjects: 2
Study 9383779 — intervention group
Group type: EXPERIMENTAL
Intervention: High-meat diet (600 g)
Number of subjects: 8
Study 9383779 — intervention group
Group type: COMPARATOR
Intervention: Low-meat diet (40 g)
Number of subjects: 8
Study 9383779 — intervention group
Group type: EXPERIMENTAL
Intervention: High-meat diet (600 g) with resistant starch (37 g)
Number of subjects: 8
Study 8936955 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon-2b (IFN-2b) at a dose of 5 MU/m2 three times a week, subcutaneously for 6 months
Number of subjects: 12
Study 8936955 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 12
Study 2782648 — intervention group
Group type: COMPARATOR
Intervention: Pediatric circle system at FGF of 0.5 x VE (C0.5)
Number of subjects: 11
Study 2782648 — intervention group
Group type: COMPARATOR
Intervention: Pediatric circle system at FGF of 1.5 x VE (C1.5)
Number of subjects: 11
Study 2782648 — intervention group
Group type: EXPERIMENTAL
Intervention: Jackson-Rees system at FGF of 1.5 x VE (JR1.5)
Number of subjects: 11
Study 2782648 — intervention group
Group type: EXPERIMENTAL
Intervention: Jackson-Rees system at FGF of 3.0 x VE (JR3.0)
Number of subjects: 11
Study 128937 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone (initially injected + Butazolidin Alka p.o.)
Number of subjects: 36
Study 128937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31394912 — intervention group
Group type: EXPERIMENTAL
Intervention: Problematic smartphone use (PSU) assessed by the Smartphone Addiction Scale‐Short Version
Number of subjects: 5063
Study 31394912 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived family communication sufficiency
Number of subjects: 5063
Study 31394912 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived family communication quality
Number of subjects: 5063
Study 28679529 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of daily calories consumed at breakfast (BF group)
Number of subjects: 0
Study 28679529 — intervention group
Group type: COMPARATOR
Intervention: 50% of daily calories consumed at dinner (D group)
Number of subjects: 0
Study 26545535 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory enteral nutrition
Number of subjects: 29
Study 26545535 — intervention group
Group type: COMPARATOR
Intervention: High ω3 enteral nutrition
Number of subjects: 29
Study 23787719 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized salt and fluid restriction (1.5 L fluid and 5 g salt daily) with dietary advice and support
Number of subjects: 97
Study 23787719 — intervention group
Group type: COMPARATOR
Intervention: Information given by nurse-led heart failure clinics (control group)
Number of subjects: 97
Study 20930017 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary KS1 data
Number of subjects: 3394
Study 20930017 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual question scores
Number of subjects: 3394
Study 19305238 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Training (IT)
Number of subjects: 41
Study 19305238 — intervention group
Group type: COMPARATOR
Intervention: Continuous Training (CT)
Number of subjects: 41
Study 16948674 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Health Impact Profile (OHIP14)
Number of subjects: 85
Study 16948674 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Impacts on Daily Performance (OIDP)
Number of subjects: 85
Study 16948674 — intervention group
Group type: EXPERIMENTAL
Intervention: OHRQoL (as measured by OIDP)
Number of subjects: 85
Study 15374557 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 24
Study 15374557 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 24
Study 11739158 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan plus cyclophosphamide (Bu-CY)
Number of subjects: 488
Study 11739158 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide plus total-body irradiation (CY-TBI)
Number of subjects: 488
Study 11739158 — intervention group
Group type: COMPARATOR
Intervention: CY-TBI
Number of subjects: 488
Study 11739158 — intervention group
Group type: EXPERIMENTAL
Intervention: Bu-CY
Number of subjects: 488
Study 11739158 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 488
Study 9236968 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent phone call intervention (reminder, counseling, scheduling)
Number of subjects: 395
Study 9236968 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthday card reminder only (standard method)
Number of subjects: 395
Study 9236968 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized letter from the medical director and materials promoting mammography
Number of subjects: 395
Study 8215552 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of 7.5% sucrose
Number of subjects: 52
Study 8215552 — intervention group
Group type: COMPARATOR
Intervention: 2 ml of sterile water (control)
Number of subjects: 52
Study 3139429 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (full and half dosage)
Number of subjects: 0
Study 3139429 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (standard and four-fold higher dose)
Number of subjects: 0
Study 3139429 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of terfenadine and ranitidine (standard and modified dosage)
Number of subjects: 0
Study 31324446 — intervention group
Group type: EXPERIMENTAL
Intervention: Benson's muscle relaxation for 10 to 20 minutes
Number of subjects: 64
Study 31324446 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study 29077725 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.15mg/kg)
Number of subjects: 104
Study 29077725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 25590215 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy + prophylactic central compartment lymph node dissection (TTx + pCCND)
Number of subjects: 181
Study 25590215 — intervention group
Group type: COMPARATOR
Intervention: Total thyroidectomy (TTx)
Number of subjects: 181
Study 23948102 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMSCs transplantation
Number of subjects: 40
Study 23948102 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cell transplantation)
Number of subjects: 40
Study 21565344 — intervention group
Group type: EXPERIMENTAL
Intervention: Headphone music
Number of subjects: 167
Study 21565344 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadcast music
Number of subjects: 167
Study 21565344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 167
Study 18708179 — intervention group
Group type: EXPERIMENTAL
Intervention: Amblyopic eye
Number of subjects: 79
Study 18708179 — intervention group
Group type: COMPARATOR
Intervention: Fellow eye
Number of subjects: 79
Study 16557616 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigenous (Black) defendant
Number of subjects: 96
Study 16557616 — intervention group
Group type: EXPERIMENTAL
Intervention: White defendant
Number of subjects: 96
Study 16557616 — intervention group
Group type: EXPERIMENTAL
Intervention: Female jurors
Number of subjects: 96
Study 16557616 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-race trials
Number of subjects: 96
Study 16557616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-race trials
Number of subjects: 96
Study 16557616 — intervention group
Group type: EXPERIMENTAL
Intervention: Female jurors in mixed-race trials
Number of subjects: 96
Study 14511223 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucalyptol
Number of subjects: 30
Study 14511223 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethylformamide (DMF)
Number of subjects: 30
Study 14511223 — intervention group
Group type: COMPARATOR
Intervention: No solvent
Number of subjects: 30
Study 10901337 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam for PMS
Number of subjects: 0
Study 10901337 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepine therapy for GAD (diazepam and lorazepam)
Number of subjects: 0
Study 8627060 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose zidovudine (180 mg/m2/dose)
Number of subjects: 426
Study 8627060 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose zidovudine (90 mg/m2/dose)
Number of subjects: 426
Study 1418392 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (120 mg/day) and nimesulide (200 mg/day)
Number of subjects: 30
Study 1418392 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (120 mg/day) and placebo
Number of subjects: 30
Study 6504947 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosage of hydrochlorothiazide (25 mg), amiloride (2.5 mg), and timolol (10 mg)
Number of subjects: 604
Study 6504947 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily dosage of hydrochlorothiazide (25 mg), amiloride (2.5 mg), and timolol (10 mg)
Number of subjects: 604
Study 6504947 — intervention group
Group type: EXPERIMENTAL
Intervention: Both once-daily and twice-daily regimens
Number of subjects: 604
Study 31798891 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment for 12 weeks
Number of subjects: 10
Study 31798891 — intervention group
Group type: COMPARATOR
Intervention: Sham-CPAP placebo for 12 weeks
Number of subjects: 10
Study 31798891 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received diabetes education and counseling
Number of subjects: 10
Study 29432286 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release carbidopa-levodopa (ER CD-LD)
Number of subjects: 484
Study 27046330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin and Prednisolone (CnP)
Number of subjects: 73
Study 27046330 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone only (P)
Number of subjects: 73
Study 25257210 — intervention group
Group type: EXPERIMENTAL
Intervention: Early non-invasive ventilation (NIV)
Number of subjects: 374
Study 25257210 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy alone
Number of subjects: 374
Study 22438520 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 IU every other day)
Number of subjects: 39815
Study 20172371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fine needle aspiration (FNA)
Number of subjects: 81
Study 20172371 — intervention group
Group type: COMPARATOR
Intervention: Traditional palpation-guided fine needle aspiration (FNA)
Number of subjects: 81
Study 18622250 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg once daily
Number of subjects: 787
Study 18622250 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 600 mg three times daily
Number of subjects: 787
Study 16208597 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib (maximum single dose: 20 mg; cumulative dose: 35 mg)
Number of subjects: 41
Study 16208597 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 41
Study 11895538 — intervention group
Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 111
Study 11895538 — intervention group
Group type: COMPARATOR
Intervention: VEH (subgingival vehicle control)
Number of subjects: 111
Study 11895538 — intervention group
Group type: EXPERIMENTAL
Intervention: DOXI (subgingival application of 15% doxycycline gel)
Number of subjects: 111
Study 9892589 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Reactive Protein (CRP) levels
Number of subjects: 936
Study 7548303 — intervention group
Group type: EXPERIMENTAL
Intervention: 2mg of VK1 orally
Number of subjects: 70
Study 7548303 — intervention group
Group type: COMPARATOR
Intervention: Control (did not receive VK)
Number of subjects: 70
Study 2183825 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 0
Study 2183825 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 0
Study 7323720 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:3 jejunoileal ratio
Number of subjects: 34
Study 7323720 — intervention group
Group type: COMPARATOR
Intervention: 3:1 jejunoileal ratio
Number of subjects: 34
Study 7323720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 34
Study 31658543 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH treatment (0.2 IU·kg(‐1)·d(‐1) subcutaneously for 7 days)
Number of subjects: 30
Study 31658543 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 30
Study 31658543 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-shock, anti-infection, and wound caring therapies)
Number of subjects: 30
Study 31658543 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 29388927 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised cycling training (SCT) for 3 months
Number of subjects: 114
Study 29388927 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking training (HBWT) for 3 months
Number of subjects: 114
Study 29388927 — intervention group
Group type: COMPARATOR
Intervention: No exercise training (control group)
Number of subjects: 114
Study 25428785 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gummy bears (7.8 g/day)
Number of subjects: 562
Study 25428785 — intervention group
Group type: COMPARATOR
Intervention: Placebo gummy bears (inulin fiber 20 g/day)
Number of subjects: 562
Study 24200027 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen conduit
Number of subjects: 43
Study 24200027 — intervention group
Group type: COMPARATOR
Intervention: Conventional microsurgical techniques (direct suture)
Number of subjects: 43
Study 21295919 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Feedback
Number of subjects: 119
Study 21295919 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 119
Study 19563189 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Source Point and Back‐Shu Point group
Number of subjects: 80
Study 19563189 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture group
Number of subjects: 80
Study 18041353 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15472191 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg/d
Number of subjects: 489
Study 15472191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 11437895 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiplash-injured subjects
Number of subjects: 0
Study 11437895 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 9564118 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (mean initial dose: 69.5 micrograms fentanyl/hr; mean final dose: 167.7 micrograms fentanyl/hr)
Number of subjects: 51
Study 9564118 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 51
Study 8091141 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (600-800 micrograms/d)
Number of subjects: 83
Study 8091141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 8091141 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with an initial gastric ulcer
Number of subjects: 83
Study 8091141 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without an initial ulcer
Number of subjects: 83
Study 3041972 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg midazolam
Number of subjects: 61
Study 3041972 — intervention group
Group type: COMPARATOR
Intervention: 15 mg oxazepam
Number of subjects: 61
Study 29652246 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release metformin (500 mg)
Number of subjects: 249
Study 29652246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 26968357 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigosertib 1800 mg per 24 h via 72-h continuous intravenous infusion administered every other week
Number of subjects: 299
Study 26968357 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 299
Study 26968357 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigosertib
Number of subjects: 299
Study 23949961 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 1700
Study 23949961 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger males
Number of subjects: 1700
Study 23949961 — intervention group
Group type: EXPERIMENTAL
Intervention: Males in connective tissue disease-associated PAH
Number of subjects: 1700
Study 23358973 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus
Number of subjects: 155
Study 23358973 — intervention group
Group type: COMPARATOR
Intervention: non-sirolimus-based regimen
Number of subjects: 155
Study 20022282 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol antagonist (4 mg/day starting on the 25th day of the previous cycle)
Number of subjects: 838
Study 20022282 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol antagonist
Number of subjects: 838
Study 20022282 — intervention group
Group type: COMPARATOR
Intervention: Long agonist (Decapeptyl 0.1 mg starting on the 20th day of the previous cycle)
Number of subjects: 838
Study 18506026 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cisplatin-based chemotherapy
Number of subjects: 4584
Study 18506026 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cisplatin-based chemotherapy with vinorelbine
Number of subjects: 4584
Study 18506026 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cisplatin-based chemotherapy with etoposide or vinca alkaloid
Number of subjects: 4584